The online TRT market did not exist at meaningful scale before 2018. In 2026, it is a $3 billion market with 19 identifiable telehealth platforms competing for patients who would previously have gone to an endocrinologist or had no treatment at all.

Here is where the market stands and what the competitive dynamics mean for patients.

The volume leaders

Maximus and Hims are the largest platforms by patient volume. Maximus has built around physician-led protocols with published research — they run clinical studies and publish findings, which is unusual in this space. Hims is a broad men's health platform where TRT is one of many offerings.

TRT Nation built its business around one thing: the lowest advertised price ($99/month labs included) and no long-term contracts. It attracted patients who were price-sensitive and skeptical of the larger platforms.

Male Excel has been around longer than most and built its reputation on personalized protocols. It positions as a premium option with higher physician involvement.

The competitive dynamics

When TRT Nation launched at $99/month with labs included, it created pricing pressure on the entire market. Competitors who had been charging $149–175/month had to respond. Several platforms have quietly reduced prices or added labs-included options since 2023.

This is good for patients. The market went from $150–200/month average in 2021 to $99–129/month for comparable programs in 2026.

The differentiation battle

With price now competitive across the market, platforms are differentiating on other factors: protocol flexibility (oral vs. injectable vs. cream), lab frequency, physician response time, HCG availability (for fertility preservation), and peptide add-on options.

DudeMeds built around FDA-approved commercial testosterone (not compounded) — which appeals to patients who specifically want non-compounded product. Defy Medical and Marek Health offer the most comprehensive protocols including ancillaries like HCG, aromatase inhibitors, and growth hormone peptides.

What to watch in the next 12 months

Consolidation. The market has too many players for all of them to survive. Expect acquisitions — either by larger health systems or by private equity rolling up the smaller platforms. When consolidation happens, prices typically stabilize or increase. If you are on a good program at a good price now, the competitive pressure keeping that price down may ease.